G1 Therapeutics, Inc. (NASDAQ: GTHX) today announced positive topline data from its Phase 2a trial evaluating trilaciclib in patients undergoing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE